Dual F/TAF formulation under evaluation by EMA

1 June 2015. Related: Antiretrovirals.

Gilead press release

On 28 May 2015, Gilead issues a press statement noting that regulatory submission for the dual formulation of FTC (emtricitabine) plus tenofovir alafenamide (TAF) has been accepted by the European Medicines Agency (EMA).

This includes two different doses for F/TAF: 200/10 mg and 200/25 mg.

Source:

Gilead press statement. European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment. (28 May 2015).
http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2054021#sthash.qmj4GCeW.dpuf